← All drugs
Drug · FAERS side-effect profile with label screen

Metoroprolol side effects: what 65,521 FDA adverse event reports show

Metoroprolol Tartrate · 1,174 reaction terms · 252,954 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Beta-adrenergic receptor inhibitor

FDA label, Indications wording of the closest related product

Label matched

Metoprolol Tartrate (Metoprolol Tartrate)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

65,521 reports · 68% serious · 7,462 with death outcome · 53% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Metoprolol Tartrate Injection, USP is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy.

FDA label, Indications and Usage

What it is

Metoprolol Tartrate Injection, USP is a selective beta 1 -adrenoreceptor blocking agent, available in 5 mL and oversized 10 mL vials for intravenous administration.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 3Lab value / disease marker 5Not in label — unassessed 32
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,134 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Brash syndrome13735.9
30.1–42.8ROR 35.9 · calibrated p 1e-4 ✓
32.2 EB05 27.9 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=137 · 100% clinicianno trial arm names this drug
Chronic kidney disease-mineral and bone disorder7925.3
20.1–31.8ROR 25.3 · calibrated p 7e-4 ✓
23.4 EB05 19.3 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=79no trial arm names this drug
Body tinea4125.0
18.2–34.4ROR 25.0 · calibrated p 9e-4 ✓
23.0 EB05 17.7 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=40 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Nephrogenic anaemia29021.1
18.7–23.8ROR 21.2 · calibrated p 0.002 ✓
19.8 EB05 18.0 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=290no trial arm names this drug
Hyperparathyroidism secondary15520.8
17.7–24.5ROR 20.9 · calibrated p 0.002 ✓
19.5 EB05 17.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=155no trial arm names this drug
Hypertensive emergency6819.7
15.4–25.2ROR 19.7 · calibrated p 0.002 ✓
18.5 EB05 15.1 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=68 · 100% clinicianno trial arm names this drug
Rebound acid hypersecretion11112.0
9.9–14.5ROR 12.0 · calibrated p 0.018 ✓
11.4 EB05 9.7 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=111no trial arm names this drug
Nephrogenic systemic fibrosis11011.9
9.8–14.4ROR 11.9 · calibrated p 0.018 ✓
11.4 EB05 9.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=108no trial arm names this drug
Echocardiogram abnormal4711.1
8.3–14.9ROR 11.1 · calibrated p 0.025 ✓
10.4 EB05 8.0 · IC025 +2.8
3/3 methods agree
Lab value / disease markerserious n=45no trial arm names this drug
Left atrial dilatation4311.0
8.1–15.0ROR 11.1 · calibrated p 0.026 ✓
10.3 EB05 7.8 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=42 · ♀ 0% (drug 53%)no trial arm names this drug
Loss of employment9410.1
8.3–12.5ROR 10.2 · calibrated p 0.032 ✓
9.7 EB05 8.1 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=93 · ♀ 100% (drug 53%)no trial arm names this drug
Essential hypertension789.9
7.9–12.4ROR 9.9 · calibrated p 0.035 ✓
9.4 EB05 7.7 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=72no trial arm names this drug
Obstructive sleep apnoea syndrome429.9
7.3–13.4ROR 9.9 · calibrated p 0.038 ✓
9.1 EB05 6.9 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=40 · ♀ 100% (drug 53%)no trial arm names this drug
End stage renal disease5359.5
8.8–10.4ROR 9.6 · calibrated p 0.037 ✓
9.3 EB05 8.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious PRR 7.9no trial arm names this drug
Fibrosis818.6
6.9–10.8ROR 8.6 · calibrated p 0.055
8.2 EB05 6.7 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=79no trial arm names this drug
Skin induration548.6
6.5–11.2ROR 8.6 · calibrated p 0.058
8.0 EB05 6.3 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=51no trial arm names this drug
Inhibitory drug interaction418.4
6.2–11.5ROR 8.4 · calibrated p 0.062
7.7 EB05 5.9 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious n=41 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Skin hypertrophy677.8
6.1–10.0ROR 7.8 · calibrated p 0.075
7.3 EB05 6.0 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=61no trial arm names this drug
Occult blood positive467.5
5.6–10.1ROR 7.5 · calibrated p 0.086
7.0 EB05 5.4 · IC025 +2.3
3/3 methods agree
Lab value / disease markerserious n=45 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Atrial flutter1847.5
6.5–8.7ROR 7.5 · calibrated p 0.082
7.2 EB05 6.4 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious PRR 6.2 · ♀ 31% (drug 53%)no trial arm names this drug
Left ventricular hypertrophy957.2
5.9–8.9ROR 7.2 · calibrated p 0.093
6.9 EB05 5.8 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious n=95no trial arm names this drug
Orthopnoea686.9
5.5–8.8ROR 6.9 · calibrated p 0.106
6.5 EB05 5.3 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=62no trial arm names this drug
Aortic stenosis716.6
5.2–8.4ROR 6.6 · calibrated p 0.119
6.3 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=70 · 100% clinicianno trial arm names this drug
Blood chloride decreased516.4
4.8–8.4ROR 6.4 · calibrated p 0.134
6.0 EB05 4.7 · IC025 +2.1
3/3 methods agree
Lab value / disease markerserious n=51no trial arm names this drug
Haemorrhagic anaemia876.3
5.1–7.8ROR 6.4 · calibrated p 0.133
6.1 EB05 5.1 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious n=87no trial arm names this drug
Renal failure chronic1496.2
5.3–7.3ROR 6.2 · calibrated p 0.139
6.0 EB05 5.2 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious PRR 5.3no trial arm names this drug
Atrial fibrillation1,8586.2
5.9–6.5ROR 6.3 · calibrated p 0.130
6.1 EB05 5.9 · IC025 +2.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.4 · serious PRR 5.2no trial arm names this drug
Coronary artery stenosis966.2
5.1–7.6ROR 6.2 · calibrated p 0.142
5.9 EB05 5.0 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious n=95no trial arm names this drug
Infection susceptibility increased405.9
4.3–8.1ROR 5.9 · calibrated p 0.163
5.5 EB05 4.2 · IC025 +1.9
3/3 methods agree
Not in label — unassessedserious n=40 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Hyperlipidaemia2165.9
5.1–6.7ROR 5.9 · calibrated p 0.161
5.7 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious PRR 5.2no trial arm names this drug
Ventricular hypokinesia585.8
4.5–7.6ROR 5.9 · calibrated p 0.167
5.5 EB05 4.4 · IC025 +2.0
3/3 methods agree
Not in label — unassessedserious n=58 · 100% clinicianno trial arm names this drug
Arteriosclerosis coronary artery1165.7
4.7–6.8ROR 5.7 · calibrated p 0.174
5.5 EB05 4.7 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious n=113no trial arm names this drug
Blood pressure systolic decreased795.7
4.5–7.1ROR 5.7 · calibrated p 0.178
5.4 EB05 4.5 · IC025 +2.1
3/3 methods agree
Lab value / disease markerserious n=71no trial arm names this drug
Renal injury5215.6
5.2–6.1ROR 5.7 · calibrated p 0.174
5.5 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious PRR 4.7no trial arm names this drug
Coronary artery occlusion2395.6
5.0–6.4ROR 5.6 · calibrated p 0.177
5.5 EB05 4.9 · IC025 +2.2
3/3 methods agree
Not in label — unassessedserious PRR 4.7no trial arm names this drug
Blood pressure inadequately controlled1055.6
4.6–6.8ROR 5.6 · calibrated p 0.181
5.4 EB05 4.6 · IC025 +2.1
3/3 methods agree
Not in label — unassessedserious n=70 · ♀ 74% (drug 53%)no trial arm names this drug
Blood phosphorus increased465.5
4.1–7.3ROR 5.5 · calibrated p 0.198
5.1 EB05 4.0 · IC025 +1.9
3/3 methods agree
Lab value / disease markerserious n=41no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Arrhythmia / qt2,5324.24.1–4.4signal
Heart failure1,8763.43.2–3.5signal
Myocardial infarction1,9173.02.9–3.2signal
Kidney injury4,0392.82.8–2.9signal
Gi bleeding1,4852.62.5–2.7signal
Anaemia2,0912.22.1–2.3signal
Hyponatraemia5472.22.0–2.4signal
Fall / fracture2,4972.12.0–2.2signal
Rhabdomyolysis / myopathy5242.11.9–2.3raised
Serious infection4,5351.91.8–1.9raised
Stroke1,4011.81.7–1.9raised
Hypoglycaemia5311.81.6–1.9raised
Venous thromboembolism1,1691.71.6–1.8raised
Hyperglycaemia / diabetes1,8491.71.6–1.8raised
Thrombocytopenia1,1651.71.6–1.8raised
Pancreatitis3841.51.4–1.7raised

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Metoroprolol (searched METOROPROLOL).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Diarrhoea (diarrhea)3,9312.0
1.9–2.0ROR 2.0 · calibrated p 0.956
2.0 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.7no trial arm names this drug
Nausea3,7971.5
1.5–1.6ROR 1.6 · calibrated p 0.690
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Dyspnoea (shortness of breath)3,7502.1
2.1–2.2ROR 2.2 · calibrated p 0.953
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.0no trial arm names this drug
Death3,0331.1
1.1–1.2ROR 1.1 · calibrated p 0.395
1.1 EB05 1.1 · IC025 +0.1Outcome field, not a reactionage-adj. PRR 1.0 · serious PRR 1.0no trial arm names this drug
Dizziness2,9971.9
1.9–2.0ROR 2.0 · calibrated p 0.931
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 2.0no trial arm names this drug
Drug ineffective (drug did not work)2,9220.7
0.7–0.7ROR 0.7 · calibrated p 0.128
0.7 EB05 0.7 · IC025 -0.6
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 0.9no trial arm names this drug
Asthenia (weakness)2,7512.3
2.3–2.4ROR 2.4 · calibrated p 0.853
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.9 · serious PRR 2.2no trial arm names this drug
Pain2,5801.3
1.3–1.4ROR 1.4 · calibrated p 0.546
1.3 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.3no trial arm names this drug
Headache2,4711.3
1.2–1.3ROR 1.3 · calibrated p 0.490
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.3no trial arm names this drug
Fall2,3712.3
2.2–2.4ROR 2.3 · calibrated p 0.885
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.6 · serious PRR 2.1no trial arm names this drug
Off label use (used outside approved label)2,3260.9
0.8–0.9ROR 0.9 · calibrated p 0.214
0.9 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 0.9no trial arm names this drug
Pneumonia (lung infection)2,0952.1
2.0–2.2ROR 2.1 · calibrated p 0.994
2.1 EB05 2.0 · IC025 +1.0Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.8no trial arm names this drug
Hypotension (low blood pressure)1,9753.2
3.0–3.3ROR 3.2 · calibrated p 0.553
3.2 EB05 3.0 · IC025 +1.6
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.7 · serious PRR 2.8no trial arm names this drug
Vomiting1,8941.3
1.2–1.4ROR 1.3 · calibrated p 0.509
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.3no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Pimavanserin Tartrate ↔ Hallucination.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Metoroprolol?

In FDA FAERS, the most frequently co-reported reaction terms for Metoroprolol are fatigue, diarrhoea, nausea, dyspnoea, dizziness, asthenia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Metoroprolol have an FDA boxed warning?

No. The FDA label retrieved for Metoroprolol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Metoroprolol causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.